Kaposi's sarcoma secondary prevention

Jump to navigation Jump to search

Kaposi's sarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Kaposi's sarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kaposi's sarcoma secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kaposi's sarcoma secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kaposi's sarcoma secondary prevention

CDC on Kaposi's sarcoma secondary prevention

Kaposi's sarcoma secondary prevention in the news

Blogs on Kaposi's sarcoma secondary prevention

Directions to Hospitals Treating Kaposi's sarcoma

Risk calculators and risk factors for Kaposi's sarcoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

Secondary prevention of Kaposi's sarcoma involves anti-retroviral therapy which can improve the CD4 T cell count.

Secondary Prevention

Secondary prevention of Kaposi's sarcoma involves anti-retroviral therapy which can improve the CD4 T cell count. Lower CD4 T cell counts (below 150 cells per microliter) are associated with worse prognosis and will result in worsening complications. Highly-active anti-retroviral therapy is important for prevention of worsening disease in patients who have Kaposi's sarcoma.[1]

References

  1. Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, Cavassini M; et al. (2008). "Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy". Br J Cancer. 99 (5): 800–4. doi:10.1038/sj.bjc.6604520. PMC 2528138. PMID 18665172.

Template:WH Template:WS


Template:WH Template:WS